Metraipolis › archive › dc_34795ae4744a

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer — Europe PMC PMID:42398129

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/42398129
DOI
10.1016/j.breast.2026.104853
License (as archived)
solo-consultazione
Archived
2026-10-18T14:22:13.923Z
SHA-256 of the archived text
efb25ee4fa52b8f8a574c2ab9094751d838ee5d44624d4e5cb5ba657f563edc6
Stable URL of this page
https://metraipolis.com/documento/dc_34795ae4744a

How to cite

Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer — Europe PMC PMID:42398129 — Europe PMC (en), https://europepmc.org/article/MED/42398129 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_34795ae4744a (Metraipolis archive dc_34795ae4744a, sha256 efb25ee4fa52b8f8a574c2ab9094751d838ee5d44624d4e5cb5ba657f563edc6)
BibTeX
@misc{dc34795ae4744a,
  title = {Antibody-drug conjugates beyond HER2: Translating evidence into practice for HR+ HER2-negative and triple-negative metastatic breast cancer — Europe PMC PMID:42398129},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/42398129},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_34795ae4744a; sha256 efb25ee4fa52b8f8a574c2ab9094751d838ee5d44624d4e5cb5ba657f563edc6},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/42398129. Agents can read the archived copy with the MCP tool read_document.